• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Summit Therapeutics(SMMT.US)

Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov20
FactSet analysts downgrade Summit Therapeutics 2025 EPS forecast
12:28
Nov18
FactSet: Summit Therapeutics 2025 EPS Forecast Revised Up to -1.42 USD
12:23
Nov10
FactSet Revises Summit Therapeutics Inc's 2025 EPS Forecast to -1.47 USD
16:23
TD Cowen Analyst Maintains Buy Rating on Summit Therapeutics
13:46
Nov7
Clear Street Analyst Maintains Buy Rating on Summit Therapeutics
18:58
Summit Therapeutics Reports Positive Phase III HARMONi-A Trial Results for Ivonescimab Plus Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer
14:01

Schedules & Filings

Schedules
Filings
Oct20
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -231.79 M, EPS -0.3117

Aug11
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -565.71 M, EPS -0.7617

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -62.91 M, EPS -0.0899

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
11.700
+185.35%
+7.540
ANGH
3.910
+68.53%
+1.587
ESHA
21.610
+50.28%
+7.230
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2797
+44.18%
+0.086
ULY
3.778
+36.89%
+1.009
RDACR
0.2493
+31.21%
+0.059
DVLT
0.6717
+30.05%
+0.157
SIDU
3.441
+28.89%
+0.780
ORIS
1.565
+28.28%
+0.345
View More